Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery

View ORCID ProfileJeroen H.A. Creemers, View ORCID ProfileWillem J. Lesterhuis, View ORCID ProfileNiven Mehra, View ORCID ProfileWinald R. Gerritsen, View ORCID ProfileCarl G. Figdor, View ORCID ProfileI. Jolanda M. de Vries, View ORCID ProfileJohannes Textor
doi: https://doi.org/10.1101/2020.10.29.20222455
Jeroen H.A. Creemers
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
4Oncode Institute, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeroen H.A. Creemers
Willem J. Lesterhuis
3School of Biomedical Sciences and Telethon Kids Institute, University of Western Australia, Perth, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Willem J. Lesterhuis
Niven Mehra
2Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niven Mehra
Winald R. Gerritsen
2Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Winald R. Gerritsen
Carl G. Figdor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
4Oncode Institute, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carl G. Figdor
I. Jolanda M. de Vries
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I. Jolanda M. de Vries
Johannes Textor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
5Data Science Department, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johannes Textor
  • For correspondence: johannes.textor@radboudumc.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background In the field of immuno-oncology, predicting treatment response or survival of cancer patients remains a challenge. Efforts to overcome these challenges focus mainly on the discovery of new biomarkers. Owing to the complexity of cancers and their tumor microenvironment, only a limited number of candidate biomarkers eventually enters clinical practice, despite advances in cellular and molecular approaches.

Methods A computational modeling approach based on ordinary differential equations was used to simulate the fundamental mechanisms that dictate tumor-immune dynamics and show its implications on responses to immune checkpoint inhibition (ICI) and patient survival. Using in silico biomarker discovery trials, we extracted fundamental principles underlying the success rates of biomarker discovery programs.

Results Our main finding is the prediction of a tipping point – a sharp state transition between immune control and immune evasion – that follows a strongly non-linear relationship between patient survival and both immunological and tumor-related parameters. In patients close to the tipping point, ICI therapy may lead to long-lasting survival benefits, whereas patients far from the tipping point may fail to benefit from these potent treatments.

Conclusion These findings have two important implications for clinical oncology. First, the apparent conundrum that ICI induces substantial benefits in some patients yet completely fails in others could be, to a large extent, explained by the presence of a tipping point. Second, predictive biomarkers for immunotherapy should ideally combine both immunological and tumor-related markers, as the distance of a patient’ status from the tipping point cannot, in general, be reliably determined from solely one of these. The notion of a tipping point in cancer-immune dynamics could help to optimize strategies in biomarker discovery to ensure accurate selection of the right patient for the right treatment.

Competing Interest Statement

WL reports consultancy activities for Douglas Pharmaceuticals and MSD; research funding from Douglas Pharmaceuticals, AstraZeneca, and ENA therapeutics; patents PCT/AU2019/050259 and PCT/AU2015/000458 (all outside this work). NM reports personal fees from Bayer and Merck Sharp & Dohme; grants and personal fees from Jansen-Cilag, Roche, Astellas, and Sanofi (all outside this work). WG reports consultancy activities for Bristol-Myers Squibb, IMS Health, Janssen-Cilag, Sanofi, and MSD; speaker fees from ESMO and MSD; and research funding from Bayer, Astellas, Janssen-Cilag, and Sanofi (all outside this work).

Funding Statement

JC was funded by the Radboudumc. WL was supported by Fellowships from the NHMRC, the Simon Lee Foundation, and the Cancer Council Western Australia. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT was supported by a Young Investigator Grant (10620) from the Dutch Cancer Society and an NWO grant (VI.Vidi.192.084).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The code of the ODE model is available at GitHub.

https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics.

  • LIST OF ABBREVIATIONS

    ICI
    Immune Checkpoint Inhibition
    ODE
    Ordinary Differential Equation
    PD-(L)1
    Programmed Death-(Ligand) 1
    TMB
    Tumor Mutational Burden
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted November 03, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
    Jeroen H.A. Creemers, Willem J. Lesterhuis, Niven Mehra, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
    medRxiv 2020.10.29.20222455; doi: https://doi.org/10.1101/2020.10.29.20222455
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
    Jeroen H.A. Creemers, Willem J. Lesterhuis, Niven Mehra, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
    medRxiv 2020.10.29.20222455; doi: https://doi.org/10.1101/2020.10.29.20222455

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (142)
    • Anesthesia (46)
    • Cardiovascular Medicine (415)
    • Dentistry and Oral Medicine (70)
    • Dermatology (48)
    • Emergency Medicine (144)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
    • Epidemiology (4861)
    • Forensic Medicine (3)
    • Gastroenterology (183)
    • Genetic and Genomic Medicine (676)
    • Geriatric Medicine (70)
    • Health Economics (192)
    • Health Informatics (630)
    • Health Policy (321)
    • Health Systems and Quality Improvement (206)
    • Hematology (85)
    • HIV/AIDS (156)
    • Infectious Diseases (except HIV/AIDS) (5343)
    • Intensive Care and Critical Care Medicine (331)
    • Medical Education (93)
    • Medical Ethics (24)
    • Nephrology (75)
    • Neurology (686)
    • Nursing (42)
    • Nutrition (115)
    • Obstetrics and Gynecology (126)
    • Occupational and Environmental Health (208)
    • Oncology (440)
    • Ophthalmology (140)
    • Orthopedics (36)
    • Otolaryngology (90)
    • Pain Medicine (35)
    • Palliative Medicine (16)
    • Pathology (129)
    • Pediatrics (194)
    • Pharmacology and Therapeutics (131)
    • Primary Care Research (84)
    • Psychiatry and Clinical Psychology (781)
    • Public and Global Health (1817)
    • Radiology and Imaging (325)
    • Rehabilitation Medicine and Physical Therapy (138)
    • Respiratory Medicine (255)
    • Rheumatology (86)
    • Sexual and Reproductive Health (69)
    • Sports Medicine (62)
    • Surgery (100)
    • Toxicology (23)
    • Transplantation (29)
    • Urology (37)